A new type of tissue model that more accurately mimics the architecture of the liver could help develop drugs to treat MASLD.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia frequently coexist, yet their causal relationship and underlying mechanisms remain poorly defined.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results